K-pop

NMIXX Returns After 5 Months… New Album 'Strange Muse' Coming Next Month

Features 6 tracks, including "Long-Held Wish" Includes their first unit song since their debut

KIM HYUNSIK
2026-09-21 08:55:20
[Edaily Starin KIM HYUNSIK Reporter] Girl group NMIXX is making a comeback with a new mini-album.
(
Photo courtesy of JYP Entertainment
)
(Photo courtesy of JYP Entertainment)
According to their agency, JYP Entertainment, on the 21st, NMIXX will release their sixth mini-album, "Strange Muse," on the 19th of next month.
This marks NMIXX’s first new release in five months since they dropped their fourth mini-album, “Heavy Serenade,” last May.
The new album features a total of six tracks, including the title track “Birthday Wish,” as well as “Kerosene,” “RudE TaLK,” “Sing to the Moon,” “Hot ‘n Unbothered,” and “WHIP.” Their agency described it as “an album with a dreamy atmosphere perfect for fall.”
Among the tracks, “Sing to the Moon” is a unit song performed by Lily and Haewon, while “Hot ‘n Unbothered” is sung by Seolyoon and Bae. “WHIP” features Jiwoo and Kyujin. This marks the first time NMIXX has included unit tracks on an album. The agency stated, “The NMIXX members personally participated in the songwriting and composition of the unit tracks, adding a touch of authenticity.”
Following the release of their new album, NMIXX will hold encore performances for their debut world tour, “EPISODE 1: ZERO FRONTIER,” at the Inspire Arena in Incheon from November 27 to 29.

Economy

Corporation

IT·Science

Economy

[VC's Pick] Riding the Wave of South Korea’s Defense Industry Boom, Digitron Sets Sights on IPO… Secures Pre-IPO Investment

This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
2026-10-09 11:11:03

Corporation

Plague Fears Boost Diagnostics; Peptron Plummets [K-bio pulse]

South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
2026-10-09 08:01:04

IT·Science

Yuhan Reduces Overseas Clinical Trials for ‘Post-Lecraza’ from 6 to 2… Impact on U.S. Approval Strategy

Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…
2026-10-09 07:31:03